Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"INO has extraordinary potential; I really want to see CEO Joseph Kim and Dave Weiner push this technology into the future." (10/24/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Patrick Cox More >
"CPRX is an emerging biotechnology company in the white hot space of orphan drug medicines." (11/7/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Scott Henry More >
"BDSI's buprenorphine product for chronic pain could be a $500M+/year revenue-generating drug if approved." (11/7/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Scott Henry More >
Companies Commented On
- Aastrom Biosciences Inc.
- Alexza Pharmaceuticals Inc.
- Amgen Inc.
- Athersys Inc.
- BioTime Inc.
- Cardinal Health Inc.
- Celgene Corp.
- Celldex Therapeutics
- Cempra Inc.
- Cyberonics Inc.
- Cytori Therapeutics Inc.
- Dendreon Corp.
- Durata Therapeutics Inc.
- Geron Corp.
- Johnson & Johnson
- Navidea Biopharmaceuticals Inc.
- NeoStem Inc.
- NuPathe Inc.
- Omeros Corp.
- Pfizer Inc.
- Roche Holding AG
- StemCells Inc.
- Trius Therapeutics Inc.
- Vision Sciences Inc.
Steve Brozak is a top-ranked analyst in biotechnology according to the Starmine ranking system. He has been in the securities industry for more than 20 years, where he has held positions in sales, management, investment banking, and research analysis. He has been intimately involved in providing research on a number of companies. Brozak has a Bachelors of Arts and a Masters in Business Administration from Columbia University and is a retired lieutenant colonel in the United States Marine Corps.
Companies that Can Mend the Biotech Market: Stephen Brozak (4/11/13) Markets are not efficient—at least not in the short term. WBB Securities President Stephen Brozak admits to frustration when he sees small-cap companies with valuations that are disengaged from market realities. But Brozak's experience as a biotech investor, banker and analyst has taught him to be patient with these disconnection syndromes, and he now delights in prospects offered by select bargain-basement opportunities. In this interview with The Life Sciences Report, Brozak touches on 10 names that have been flying far below the radars of most investors.
Stephen Brozak: Changing the Way Money Is Made and Diseases Are Cured (1/24/13) Stephen Brozak doesn't mess around. He focuses on technologies poised to change the way medicine has been practiced for thousands of years. As president of WBB Securities, Brozak is talking to his clientele about revolutionary stem cell therapies that deal with disease in totally new ways. He's also bullish on new antibiotics—important innovations in a world facing a shortage of effective drugs and a potential crisis of catastrophic proportion. In this interview with The Life Sciences Report, Brozak talks up must-hear ideas that growth investors need to consider.
Make Friends with Companion Diagnostics to Bolster Your Biotech Portfolio: Stephen Brozak (5/24/12) Hitting just the right target and engineering cells to perform certain tasks will unlock the deep secrets of biology and change the entire paradigm of medicine, says WBB Securities President and Managing Partner Stephen Brozak. He is not picking the ultimate winners just yet, but he is playing stem cell and personalized medicine developers as a diversified portfolio, knowing that successes will overpower the also-rans. In this exclusive interview with The Life Sciences Report, Brozak shares names from his list of finalists.
"NBS has crossed the 50% enrollment mark on its PreSERVE-AMI phase 2 clinical trial; safety looks good and enrollment should be completed this year." (4/11/13) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >
"CPRX has a few programs in indications that are less crowded and do not have many successful treatment options." (11/26/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Michael Hay More >
"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay More >
"We expect FDA approval in the near term—likely by the end of the year—for OCLS' Microcyn Hydrogel device." (11/26/13) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Jocelyn August More >